Table 1.

Principal molecular classifications in Thymic Epithelial Tumors (TETs).

First Author, Year	Molecular Subtypes	Typical Genomic Profile	Enriched for MG	Main Histotypes	Prognosis
Radovich M et al. 2018	1 (B-like)	wtGTF2I, wtRAS, ↓p53, ↑MYC/MAX, ↓PPARA-RXRA, ↓XBP1-2, ↑MYB	+	B	Intermediate
	2 (C-like)	wtGTF2I, wtRAS, chr16q loss, ↓p53, ↑MYC/MAX, ↓XBP1-2, ↓PPARA-RXRA, ↑MYB	₋	C	Poor
	3 (AB-like)	mGTF2I, wtRAS, ↑C19MC, ↑MYB, ↓p53, ↑FOXM1, ↓TAp73a, ↑E2F1/DP	₋	AB	Good
	4 (A-like)	mGTF2I, mRAS, ↑C19MC, ↑p53, ↑XBP1-2, ↓MYC/MAX, ↓MYB, ↓FOXM1	₋	A and AB	Good
Lee HS et al. 2017	GTF2I	mGTF2I	₋	A and AB	Good
	TS	wtGTF2I, ↑genes associated with TS	±	AB, B1 and B2	Good
	CS	wtGTF2I, sCNA low	+	B2	Poor
	CIN	wtGTF2I, sCNA high, delCDKN2A	+	B2, B3 and C	Poor

Abbreviations: MG, myasthenia gravis; m, mutated; wt, wild-type; ↑, overexpressed; ↓, underexpressed; chr, chromosome; TS, T-cell signaling; CS, chromosomal stability; CIN, chromosomal instability; sCNA, somatic copy number alterations; del, deletion.